The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease (Q36987446)

17 August 2017

1 reference

title

The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease (English)

1 reference

17 August 2017

Katherine L O'Brien

2

0 references

Hoosen Coovadia

series ordinal

6

object named as

Hoosen Coovadia

1 reference

17 August 2017

7

Orin S Levine

1 reference

17 August 2017

5

Philippa Musoke

1 reference

17 August 2017

Sandra J Bliss

1

1 reference

17 August 2017

Edward N Janoff

series ordinal

3

1 reference

17 August 2017

Mark F Cotton

series ordinal

4

1 reference

17 August 2017

language of work or name

1 reference

31 October 2007

1 reference

Lancet Infectious Diseases

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

67-80

1 reference

17 August 2017

1

1 reference

Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Streptococcus pneumoniae colonization, bacteremia, and immune response among persons with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Global strategies to prevent bacterial pneumonia in adults with HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: implications for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacterial pneumonia in HIV-infected patients: a prospective study of 68 episodes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacteraemia and mortality among adult medical admissions in Malawi--predominance of non-typhi salmonellae and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Acute community-acquired bacterial pneumonia in Human Immunodeficiency Virus (HIV) infected and non-HIV-infected adult patients in Cameroon: aetiology and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacteremia in febrile human immunodeficiency virus-infected children presenting to ambulatory care settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Pneumonia in HIV-infected patients in the HAART era: Incidence, risk, and impact of the pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Impact of human immunodeficiency virus type 1 infection on the epidemiology and outcome of bacterial meningitis in South African children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

The effect of HIV infection on paediatric bacterial meningitis in Blantyre, Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacterial infections in human immunodeficiency virus type 1-infected children: the impact of central venous catheters and antiretroviral agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacterial infections in human immunodeficiency virus-infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Pneumococcal bacteremia during a decade in children in Soweto, South Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Pneumococcal bacteremia in adults in Soweto, South Africa, during the course of a decade

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Aetiology and clinical presentation of mild community-acquired bacterial pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

A 3-year prospective study of a urinary antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and clinical impact on the reported etiology.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacteriologic diagnosis of acute pneumonia. Comparison of sputum, transtracheal aspirates, and lung aspirates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Invasive pneumococcal infections in children infected with HIV are not associated with splenic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Invasive pneumococcal infections in human immunodeficiency virus-infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Observational cohort study of HIV-infected African children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Streptococcus pneumoniae in human immunodeficiency virus type 1-infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Recurrent Invasive Pneumococcal Disease: A Population-Based Assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacterial pneumonia in patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacteremia in HIV-positive and AIDS patients: incidence, species distribution, risk-factors, outcome, and influence of long-term prophylactic antibiotic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Favorable prognosis of purulent meningitis in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Is the recommendation for pneumococcal vaccination of HIV patients evidence based?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Recurrent pneumococcal bacteremia: risk factors and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Prevalence, serotypes, and risk factors for pneumococcal carriage among HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Nasopharyngeal colonization with Streptococcus pneumoniae in children infected with human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Incidence of opportunistic and other infections in HIV-infected children in the HAART era.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Streptococcus pneumoniae bacteremia in children infected with HIV: presentation, course, and outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Invasive pneumococcal disease in Jamaican children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Community-acquired bacteremia in patients with acquired immunodeficiency syndrome: clinical presentation, bacteriology, and outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Pneumococcal bacteremia with pneumonia. Mortality in acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Streptococcus pneumoniae bacteremia in a community hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Bacteremia in hospitalized patients with human immunodeficiency virus: A prospective, cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Changes in the epidemiology of pneumococcal bacteremia in a Swiss university hospital during a 15-year period, 1986-2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Differences in presentation and outcome of invasive pneumococcal disease among patients with and without HIV infection in the pre-HAART era.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Streptococcus pneumoniae and Legionella pneumophila pneumonia in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Constancy of distribution of serogroups of invasive pneumococcal isolates among children: experience during 4 decades.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes, in HIV-infected and -uninfected adults with pneumococcal bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Multistate evaluation of invasive pneumococcal diseases in adults with human immunodeficiency virus infection: serotype and antimicrobial resistance patterns in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Viral load response to a pneumococcal conjugate vaccine, polysaccharide vaccine or placebo among HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Spread of Streptococcus pneumoniae in Families. I. Carriage Rates and Distribution of Types

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Progress in the prevention of pneumococcal infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Colonization by Streptococcus pneumoniae among human immunodeficiency virus-infected adults: prevalence of antibiotic resistance, impact of immunization, and characterization by polymerase chain reaction with BOX primers of isolates from persistent

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Nasopharyngeal pneumococcal colonization among Kenyan children: antibiotic resistance, strain types and associations with human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Colonization by Streptococcus penumoniae in human immunodeficiency virus-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Secondary Pneumocystis carinii pneumonia prophylaxis with trimethoprim-sulphamethoxazole does not prevent bacterial pneumonia in HIV-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970242-6

7 January 2021

10.1016/S1473-3099(07)70242-6

Identifiers

DOI

1 reference

17 August 2017

1 reference